April 3, 2024 by admin aurigene Development of novel anti-SIRPα/β dual antibody with single-agent phagocytosis activity
April 3, 2024 by admin aurigene A novel CCR4 antagonist induces potent anti-tumor response through inhibition of Treg migration into the tumor microenvironment
April 3, 2024 by admin aurigene Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
April 3, 2024 by admin aurigene Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
April 3, 2024 by admin aurigene Discovery of potent and paralog selective PROTAC degraders of CBP or p300 proteins for the treatment of various cancers
April 3, 2024 by admin aurigene Potent anti-tumor activity of a selective and orally bioavailable reversible covalent CDK12 inhibitor
April 3, 2024 by admin aurigene Discovery of AUR-112, a novel MALT1 protease inhibitor for the treatment of B cell lymphomas
April 3, 2024 by admin aurigene Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers
April 3, 2024 by admin aurigene Targeting CBP/p300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy
September 15, 2023 by admin aurigene Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion, and Therapeutic Resistance Aurigene’s AUR109_DDR1-SIK2-Wnt-Catenin inhibitor for PFI2023 v2